Andera Partners

Founded 1953

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 161
Average round size
info
The average size of a deal this fund participated in
$23M
Portfolio companies 120
Rounds per year 2.37
Lead investments 43
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.27
Exits 47
Key employees 28
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Medical Device
Summary

In 1953 was created Andera Partners, which is appeared as VC. The fund was located in Europe if to be more exact in France. The main department of described VC is located in the Paris.

We also calculated 28 valuable employees in our database.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Andera Partners, startups are often financed by Neomed Management, Omnes Capital, Ysios Capital. The meaningful sponsors for the fund in investment in the same round are Omnes Capital, Idinvest Partners, Gimv. In the next rounds fund is usually obtained by Neomed Management, VI Partners AG, Omnes Capital.

The real fund results show that this VC is 20 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Andera Partners performs on 0 percentage points more the average number of lead investments. The top amount of exits for fund were in 2015. The fund is constantly included in 7-12 investment rounds annually. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the various public portfolio startups of the fund, we may underline Vivoryon Therapeutics, AM Pharma, Arvelle Therapeutics The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Manufacturing, Health Diagnostics.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

T-knife

Biotechnology
$110M02 Aug 2021 Berlin, Berlin, Germany

Artios Pharma

Biopharma
Biotechnology
Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Klubb

Industrial
Industrial Engineering
Manufacturing
26 Jul 2021 Ferrières-en-Brie, Seine-et-Marne, France

AgomAb Therapeutics

Biotechnology
Health Care
Therapeutics
$74M10 Mar 2021 East Flanders

Atlantic Therapeutics

Fitness
Health Care
Specialty Retail
Therapeutic Devices
Therapeutics
08 Mar 2021 Galway, Galway, Ireland

Medlumics

Biotechnology
CRM
Health Care
Hospital
Information Technology
Medical Device
Robotics
$21M10 Feb 2021 Community of Madrid

Consulting
SaaS
08 Jan 2021 Ile-de-France

ReViral

Biotechnology
Health Care
Medical
Therapeutics
$44M25 Aug 2020 England

T-knife

Biotechnology
$77M06 Aug 2020 Berlin
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Andera Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: